National Community Pharmacists Association

Based in VA

🤖

AI Overview

With $15.4M in lobbying spend across 34 quarterly filings, National Community Pharmacists Association is one of the biggest lobbying spenders in Washington. They deploy 14 individual lobbyists Their lobbying covers 13 issue areas. Active from 2018 to 2025.

$15.4M

Total Spend

Years Active

Firms Hired

Lobbyists Deployed

Issues Lobbied

Spending Trend

View as table

Year	Lobbying Spend
2018	$1.3M
2019	$1.3M
2020	$1.5M
2021	$3.7M
2022	$3.2M
2023	$1.4M
2024	$1.8M
2025	$1.3M

Issues Lobbied

Alcohol & Drug Abuse Health Issues Medicare/Medicaid Defense Budget/Appropriations Animals Pharmacy Taxation Labor Issues Insurance Small Business Telecommunications Trade

Lobbying Firms

National Community Pharmacists Association

Lobbyists

Karry La Violette Ronna Hauser Phillip Harbison Kevin Schweers Susan Pilch Kala Shankle Anne Cassity Reema Taneja Shion Chang Peter Mihalick Matthew Seiler Kaitlin Krell Steven Postal David Weissman

What They Lobby About

These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Alcohol & Drug Abuse, Health Issues, Medicare/Medicaid, Defense, Budget/Appropriations and 8 more

•Implementation of Public Law 114-198 pharmacy provisionsÍ¾
•Implementation of Public Law 114-255 pharmacy provisions;
•H.R. 1854/S. 778, Prescription Drug Monitoring Act of 2017;
•S 892 / H.R

•S. 469, Affordable and Safe Prescription Drug Importation Act;
•H.R. 1245, Affordable and Safe Prescription Drug Importation Act;
•H.R. 1776, Improving Access to Affordable Prescription Drugs Act;
•S.

•H.R. 1316, Prescription Drug Price Transparency ActÍ¾
•H.R. 1038, Improving Transparency and Accuracy in Medicare Part D Spending Act;
•S. 413, Improving Transparency and Accuracy in Medicar

•Tricare pharmacy working group

•Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations ActÍ¾
•H.R. 2430 the FDA Reauthorization Act (FDARA) of 2017;
•S.934 FDA Reauthorization A